Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Andrographolide DMD - InnoBioscience

Next Previous
Drug Profile

Andrographolide DMD - InnoBioscience

Alternative Names: Andrographolide-DMD-InnoBioscience; Andrographolide-Duchenne muscular dystrophy-InnoBioscience; IB DMD

Latest Information Update: 28 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InnoBioscience
  • Class Anti-inflammatories; Antidementias; Antifibrotics; Antineoplastics; Naphthalenes; Small molecules
  • Mechanism of Action Beta catenin stimulants; Cell cycle inhibitors; Connective tissue growth factor inhibitors; Glycogen synthase kinase 3 beta inhibitors; NF-kappa B kinase inhibitors; Nitric oxide inhibitors; Phospholipase C inhibitors; Protein kinase C inhibitors; Wnt signalling pathway stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Duchenne muscular dystrophy; Fibrosis

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral, Injection)
  • 28 Apr 2022 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (PO)
  • 28 Apr 2022 No recent reports of development identified for preclinical development in Fibrosis in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top